SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Timothy Schmidt; Zhubin Gahvari; Natalie S Callander

doi:10.1016/j.clml.2024.03.008

SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Clin Lymphoma Myeloma Leuk. 2024 Mar 16:S2152-2650(24)00115-0. doi: 10.1016/j.clml.2024.03.008. Online ahead of print.

Authors

Timothy Schmidt¹, Zhubin Gahvari¹, Natalie S Callander²

Affiliations

¹ Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison WI.
² Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison WI. Electronic address: nsc@medicine.wisc.edu.

PMID: 38641486
DOI: 10.1016/j.clml.2024.03.008

Abstract

Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. In this review, we summarize the current diagnosis treatment guidelines for MGUS and SMM and highlight recent advances that underscore a shifting paradigm in the evaluation and management of plasma cell precursor conditions.

Keywords: MGUS; MM; Risk stratification; SMM; Screening.

Publication types

Review